{"id":"https://openalex.org/W2768517818","doi":"https://doi.org/10.1177/2040622317738910","title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","display_name":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","alternate_titles":[],"publication_year":2017,"publication_date":"2017-11-16","ids":{"openalex":"https://openalex.org/W2768517818","doi":"https://doi.org/10.1177/2040622317738910","mag":"2768517818","pmid":"https://pubmed.ncbi.nlm.nih.gov/29344327","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5761942"},"language":"en","primary_location":{"id":"doi:10.1177/2040622317738910","doi":"https://doi.org/10.1177/2040622317738910","is_oa":true,"landing_page_url":"https://doi.org/10.1177/2040622317738910","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/2040622317738910","source":{"id":"https://openalex.org/S101854828","display_name":"Therapeutic Advances in Chronic Disease","issn_l":"2040-6223","issn":["2040-6223","2040-6231"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Chronic Disease","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2768517818"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://journals.sagepub.com/doi/pdf/10.1177/2040622317738910","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003492421","display_name":"Jillian Frieder","orcid":"https://orcid.org/0000-0002-9108-5577","observed_orcids":["https://orcid.org/0000-0002-9108-5577","https://orcid.org/0000-0002-3987-005X"]},"institutions":[{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jillian Frieder","raw_affiliation_strings":["Baylor Scott and White- Division of Dermatology, Dallas, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Scott and White- Division of Dermatology, Dallas, TX, USA","institution_ids":["https://openalex.org/I4210160418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010294328","display_name":"Dario Nicolas Kivelevitch","orcid":"https://orcid.org/0000-0002-0247-9962","observed_orcids":["https://orcid.org/0000-0002-0247-9962"]},"institutions":[{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dario Kivelevitch","raw_affiliation_strings":["Baylor Scott and White- Division of Dermatology, Dallas, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Scott and White- Division of Dermatology, Dallas, TX, USA","institution_ids":["https://openalex.org/I4210160418"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075798284","display_name":"Alan Menter","orcid":"https://orcid.org/0000-0002-9314-0007","observed_orcids":["https://orcid.org/0000-0002-9314-0007"]},"institutions":[{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alan Menter","raw_affiliation_strings":["Baylor Scott and White- Division of Dermatology, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Scott and White- Division of Dermatology, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA","institution_ids":["https://openalex.org/I4210160418"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5075798284"],"corresponding_institution_ids":["https://openalex.org/I4210160418"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":null,"fwci":1.8246,"has_fulltext":true,"cited_by_count":208,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.86379928,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"9","issue":"1","first_page":"5","last_page":"21"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":1.0},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.9319999814033508},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.8209999799728394},{"id":"https://openalex.org/keywords/psoriatic-arthritis","display_name":"psoriatic arthritis","score":0.8349999785423279},{"id":"https://openalex.org/keywords/ankylosing-spondylitis","display_name":"ankylosing spondylitis","score":1.0},{"id":"https://openalex.org/keywords/th17-pathway","display_name":"Th17 pathway","score":0.7419999837875366},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8679999709129333},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.9660000205039978},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.7049999833106995},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":1.0},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.8109999895095825},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.9764770269393921},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9494720697402954},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.898388683795929},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7452799677848816},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.7444299459457397},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.660962700843811},{"id":"https://openalex.org/C156730664","wikidata":"https://www.wikidata.org/wiki/Q23308590","display_name":"Interleukin 23","level":4,"score":0.6525171399116516},{"id":"https://openalex.org/C2777402515","wikidata":"https://www.wikidata.org/wiki/Q52849","display_name":"Ankylosing spondylitis","level":2,"score":0.5516874194145203},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5389189720153809},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5077496767044067},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.45577502250671387},{"id":"https://openalex.org/C47348012","wikidata":"https://www.wikidata.org/wiki/Q99486570","display_name":"Interleukin 17","level":3,"score":0.4487961530685425},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.4421631693840027},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.35178500413894653},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.32545334100723267},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.2180461287498474},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21097099781036377}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1177/2040622317738910","doi":"https://doi.org/10.1177/2040622317738910","is_oa":true,"landing_page_url":"https://doi.org/10.1177/2040622317738910","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/2040622317738910","source":{"id":"https://openalex.org/S101854828","display_name":"Therapeutic Advances in Chronic Disease","issn_l":"2040-6223","issn":["2040-6223","2040-6231"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Chronic Disease","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5761942","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5761942/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ther Adv Chronic Dis","raw_type":"Text"},{"id":"pmid:29344327","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29344327","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic advances in chronic disease","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1177/2040622317738910","doi":"https://doi.org/10.1177/2040622317738910","is_oa":true,"landing_page_url":"https://doi.org/10.1177/2040622317738910","pdf_url":"https://journals.sagepub.com/doi/pdf/10.1177/2040622317738910","source":{"id":"https://openalex.org/S101854828","display_name":"Therapeutic Advances in Chronic Disease","issn_l":"2040-6223","issn":["2040-6223","2040-6231"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Therapeutic Advances in Chronic Disease","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2768517818.pdf","grobid_xml":"https://content.openalex.org/works/W2768517818.grobid-xml"},"referenced_works_count":65,"referenced_works":["https://openalex.org/W1483095827","https://openalex.org/W1508752722","https://openalex.org/W1515251814","https://openalex.org/W1552422862","https://openalex.org/W1556165793","https://openalex.org/W1885801568","https://openalex.org/W1971708477","https://openalex.org/W1971917916","https://openalex.org/W1973354423","https://openalex.org/W1975162362","https://openalex.org/W1979058179","https://openalex.org/W1980504592","https://openalex.org/W1982598880","https://openalex.org/W1983986523","https://openalex.org/W1987784314","https://openalex.org/W1993273784","https://openalex.org/W2016898503","https://openalex.org/W2020233428","https://openalex.org/W2028049627","https://openalex.org/W2030972148","https://openalex.org/W2035941649","https://openalex.org/W2044280032","https://openalex.org/W2047344004","https://openalex.org/W2056468769","https://openalex.org/W2059276529","https://openalex.org/W2060527543","https://openalex.org/W2068089617","https://openalex.org/W2080237150","https://openalex.org/W2080390872","https://openalex.org/W2096620879","https://openalex.org/W2103018315","https://openalex.org/W2103524303","https://openalex.org/W2103750969","https://openalex.org/W2112006696","https://openalex.org/W2112172463","https://openalex.org/W2127834887","https://openalex.org/W2132784721","https://openalex.org/W2136517791","https://openalex.org/W2151209321","https://openalex.org/W2151280501","https://openalex.org/W2153511580","https://openalex.org/W2279719049","https://openalex.org/W2281983923","https://openalex.org/W2322390243","https://openalex.org/W2327252657","https://openalex.org/W2331102181","https://openalex.org/W2359919307","https://openalex.org/W2386234576","https://openalex.org/W2408458962","https://openalex.org/W2439238989","https://openalex.org/W2521243079","https://openalex.org/W2529225914","https://openalex.org/W2529389767","https://openalex.org/W2535494101","https://openalex.org/W2553675694","https://openalex.org/W2557156446","https://openalex.org/W2568858752","https://openalex.org/W2582775258","https://openalex.org/W2613244920","https://openalex.org/W2619788345","https://openalex.org/W2621467536","https://openalex.org/W2621777477","https://openalex.org/W2742484040","https://openalex.org/W2745845806","https://openalex.org/W4250753642"],"related_works":["https://openalex.org/W2591728499","https://openalex.org/W2974793973","https://openalex.org/W2187975315","https://openalex.org/W2809186224","https://openalex.org/W2199113350","https://openalex.org/W2531630828","https://openalex.org/W4389648740","https://openalex.org/W2244667578","https://openalex.org/W2988256765","https://openalex.org/W2586220284"],"abstract_inverted_index":{"Psoriasis":[0],"is":[1,24,63,158,186],"a":[2,11,32,64,146,187],"systemic":[3],"inflammatory":[4],"disease":[5],"associated":[6,160],"with":[7,145,153,161,182],"numerous":[8,121],"comorbidities":[9],"and":[10,40,58,70,83,107,124,143,185],"profound":[12],"impact":[13],"on":[14],"patients'":[15],"quality":[16,166],"of":[17,35,89,103,167],"life.":[18],"While":[19],"its":[20,41,59,74],"complex":[21],"immune":[22],"pathogenesis":[23],"still":[25],"not":[26],"fully":[27,65],"delineated,":[28],"current":[29,138,192],"evidence":[30],"supports":[31],"fundamental":[33],"role":[34],"the":[36,71,80,87,101,173],"T-helper-17":[37],"(TH-17)":[38],"pathway":[39],"related":[42],"interleukin-17":[43],"(IL-17)":[44],"cytokine.":[45],"Thus,":[46,170],"new":[47],"antipsoriatic":[48,193],"therapies":[49],"have":[50],"been":[51,98,117],"developed":[52],"to":[53,76,91,137,190],"block":[54],"this":[55],"key":[56],"cytokine":[57],"downstream":[60],"effects.":[61],"Secukinumab":[62],"humanized,":[66],"monoclonal":[67],"anti-IL-17A":[68],"antibody,":[69],"first":[72],"in":[73,113,120,134,164],"class":[75],"be":[77],"approved":[78,99],"by":[79],"US":[81],"Food":[82],"Drug":[84],"Administration":[85],"for":[86,100,175],"treatment":[88,102],"moderate":[90],"severe":[92],"plaque":[93,114],"psoriasis.":[94],"It":[95],"has":[96,116,131],"also":[97,159],"active":[104],"psoriatic":[105],"arthritis":[106],"ankylosing":[108],"spondylitis.":[109],"Its":[110],"clinical":[111,126,135],"efficacy":[112],"psoriasis":[115],"well":[118],"demonstrated":[119],"phase":[122],"II":[123],"III":[125],"trials.":[127],"In":[128,151],"addition,":[129],"it":[130],"shown":[132],"superiority":[133],"trials":[136],"biologic":[139],"agents":[140],"including":[141],"etanercept":[142],"ustekinumab,":[144],"safe":[147],"adverse":[148],"event":[149],"profile.":[150],"correlation":[152],"excellent":[154],"skin":[155],"improvements,":[156],"secukinumab":[157,171],"significant":[162],"improvements":[163],"health-related":[165],"life":[168],"measures.":[169],"offers":[172],"potential":[174],"equal,":[176],"or":[177],"improved,":[178],"therapeutic":[179],"effects":[180],"compared":[181],"other":[183],"biologics,":[184],"valuable":[188],"addition":[189],"our":[191],"armamentarium.":[194]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2768517818","counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":16},{"year":2024,"cited_by_count":23},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":37},{"year":2021,"cited_by_count":29},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":37},{"year":2018,"cited_by_count":16}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2017-12-04T00:00:00"}
